Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.57 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.57 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.57 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | DUT | P33316 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265714 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL19537371 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL19534525 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12621455 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12658368 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL23880678 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12939575 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL474592 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL14853791 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL16169491 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2023-03-02 | — | — | US | disclosed |
| EP-3043803-B1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND THEIR USES | UNIV EMORY (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | EMORY UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210060050-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | EMORY UNIVERSITY | 2021-03-04 | — | — | US | disclosed |
| US-10874683-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-20190083520-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-03-21 | — | — | US | disclosed |
| US-20190022116-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-01-24 | — | — | US | disclosed |
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | BANK OF AMERICA, N.A. | 2015-03-19 | — | — | US | disclosed |
| US-8927513-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | P2RY2 452/4885P2RY4 288/4885SLC29A1 15/4885 |
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | PNP, NTPCR, TYMP | P2RY2 418/4885P2RY4 311/4885SLC29A1 32/4885 |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | P2RY2 1456/4885P2RY4 1016/4885SLC29A1 127/4885 |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | P2RY2 1517/4885P2RY4 1077/4885SLC29A1 139/4885 |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | P2RY2 316/4885P2RY4 230/4885SLC29A1 8/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | P2RY2 89/4885P2RY4 66/4885SLC29A1 5/4885 |
| US-10874683-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | TYMP, DCTD, MTAP | P2RY2 579/4885P2RY4 170/4885SLC29A1 43/4885 |
| US-20190022116-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ENTPD5, ADA | P2RY2 1364/4885P2RY4 592/4885SLC29A1 57/4885 |
| US-20190083520-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, DCTD, MTAP | P2RY2 579/4885P2RY4 170/4885SLC29A1 43/4885 |
| US-20210060050-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ENTPD5, ADA | P2RY2 1364/4885P2RY4 592/4885SLC29A1 57/4885 |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, PNP, NTPCR | P2RY2 606/4885P2RY4 422/4885SLC29A1 31/4885 |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, NTPCR, PNP | P2RY2 691/4885P2RY4 446/4885SLC29A1 29/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | P2RY2 452/4885P2RY4 288/4885SLC29A1 15/4885 |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ADA, CDA | P2RY2 1313/4885P2RY4 561/4885SLC29A1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.